相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Developments in Ki67 and other biomarkers for treatment decision making in breast cancer
A. Sheri et al.
ANNALS OF ONCOLOGY (2012)
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Manfred Kaufmann et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
Milvia Zambetti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
Andrea Cavazzoni et al.
CANCER LETTERS (2012)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short-term future?
Nadia Margariti et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer
Marco Colleoni et al.
EUROPEAN JOURNAL OF CANCER (2010)
Early-Stage Favorable Hodgkin's Lymphoma: Is Chemotherapy Alone Sufficient? Reply
George P. Canellos
JOURNAL OF CLINICAL ONCOLOGY (2010)
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
Daniele Generali et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Ute E. Krainick-Strobel et al.
BMC CANCER (2008)
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Alfredo Berruti et al.
ONCOLOGIST (2008)
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
Brigitte Mlineritsch et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy
Sadako Akashi-Tanaka et al.
BREAST (2007)
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
Alberto Bottini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
T Petit et al.
EUROPEAN JOURNAL OF CANCER (2004)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older
R Yancik et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease
C Fiorentino et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
分享论文
